Nanoviricides, Inc. (NYSE: NNVC), an SEC filer in Pharmaceutical Preparations, closed at $1.24, -3.1%, on 2026-08-28, with a market cap of $28M as of 2026-08-27 and a return on equity of -99.7%. Institutional ownership, earnings history and filed financials are on the tabs below.
Returns use ADJUSTED closes (splits + dividends).
Volume as VALUE TRADED — close × volume, in USD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | NNVC | SPY | Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 · ytd | −14.6% | +8.8% | −13.1% | +36.0% | +43.5% | −22.5% | +10.1% | −18.4% | — | — | — | — | +9.7% | +13.4% | −3.7pp |
| 2025 | −16.1% | +10.0% | −11.4% | +17.1% | +10.9% | −7.9% | +15.7% | −14.2% | +2.9% | +16.1% | −26.5% | −7.4% | −21.0% | +17.7% | −38.7pp |
| 2024 | +8.8% | +21.6% | −14.1% | +3.4% | +100.0% | −28.3% | +26.7% | −10.6% | −23.1% | −4.7% | −4.9% | +5.1% | +40.2% | +24.9% | +15.3pp |
| 2023 | +27.6% | −2.5% | −15.2% | +13.7% | −21.1% | +9.5% | +34.8% | −6.5% | −7.6% | −15.7% | +1.8% | −11.3% | −8.1% | +26.2% | −34.3pp |
| 2022 | −36.3% | −19.8% | +10.0% | −28.7% | +34.2% | −6.0% | −3.2% | +31.3% | −27.6% | −0.6% | −7.6% | −30.2% | −70.2% | −18.2% | −52.0pp |
| 2021 | +40.8% | +3.5% | +12.9% | −12.1% | −13.5% | +29.2% | −13.4% | −3.7% | +19.9% | +2.2% | −0.4% | −21.2% | +29.6% | +28.7% | +0.9pp |
| 2020 | +567.7% | −43.3% | −39.6% | +4.5% | +25.3% | −0.5% | −17.8% | −35.4% | −3.3% | −10.2% | +13.3% | −26.6% | +14.3% | +18.3% | −4.0pp |
| 2019 | +49.0% | +27.5% | −28.9% | −6.9% | +9.4% | −12.7% | −6.9% | −6.0% | −51.2% | +2.9% | +30.6% | −8.9% | −37.3% | +31.2% | −68.5pp |
| 2018 | +0.6% | +3.9% | −10.6% | −14.7% | −20.8% | −20.8% | −11.4% | +7.7% | −14.3% | −11.2% | +14.6% | −45.4% | −77.3% | −4.6% | −72.7pp |
| 2017 | +7.5% | +3.5% | −5.9% | +9.8% | +0.0% | +9.8% | +5.9% | −4.9% | −16.2% | −7.0% | −2.8% | −14.6% | −17.7% | +21.7% | −39.5pp |
Month-end over prior month-end; a blank cell is no return.
Basis. Both columns share one basis, so Δ is like-for-like.
End-of-day closes; a “ytd” or “part” year is not a full year.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years ⓘ | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 20 | 21 | 21 |
| Positive ⓘ | 67% | 62% | 38% | 48% | 57% | 38% | 38% | 33% | 30% | 40% | 38% | 24% |
| Median | +2.6% | +3.5% | −8.5% | +0.0% | +9.4% | −7.9% | −3.3% | −6.0% | −7.7% | −2.9% | −4.9% | −7.0% |
| Best | +567.7% | +79.9% | +57.3% | +44.7% | +100.0% | +29.2% | +38.2% | +39.1% | +57.4% | +27.0% | +50.9% | +32.8% |
| Worst | −36.3% | −43.3% | −39.6% | −28.7% | −29.7% | −28.3% | −26.1% | −47.2% | −51.2% | −23.0% | −34.0% | −45.4% |
| vs SPY ⓘ | +5.7pp | +5.4pp | −7.6pp | −4.4pp | +6.3pp | −9.8pp | −2.7pp | −5.2pp | −7.7pp | −5.8pp | −10.6pp | −7.5pp |
250 monthly observations · 2005–2026 · benchmark SPY
